Search Results
Sep 08, 2026, 08:00 ET Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SHELTON, Conn., Sept. 8, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies
More news about: Intensity Therapeutics Inc.
Aug 11, 2026, 07:30 ET Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Conn., Aug. 11, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill
More news about: Intensity Therapeutics Inc.
Aug 04, 2026, 08:00 ET Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill
More news about: Intensity Therapeutics Inc.
Jul 15, 2026, 07:45 ET Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill
More news about: Intensity Therapeutics Inc.
Jul 02, 2026, 10:31 ET Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
Merck, Kelun-Biotech, CSPC Pharmaceutical, Shanghai JMT-Bio, Bristol-Myers Squibb, AbbVie, Lantern Pharma, Wayshine Biopharm, Teligene US, Genprex, J Ints Bio, Black Diamond Therapeutics, BlossomHill Therapeutics, Scorpion Therapeutics, Pierre Fabre, Antares Therapeutics, A2 Biotherapeutics, BioNTech,
More news about: DelveInsight Business Research, LLP
Jul 01, 2026, 08:00 ET Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
Conn., July 1, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill
More news about: Intensity Therapeutics Inc.
Jun 15, 2026, 12:31 ET EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight
Merck, Kelun-Biotech, CSPC Pharmaceutical, Shanghai JMT-Bio, Bristol-Myers Squibb, AbbVie, Lantern Pharma, Wayshine Biopharm, Teligene US, Genprex, J Ints Bio, Black Diamond Therapeutics, BlossomHill Therapeutics, Scorpion Therapeutics, Pierre Fabre, Antares Therapeutics, A2 Biotherapeutics, BioNTech,
More news about: DelveInsight Business Research, LLP
May 14, 2026, 08:00 ET Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies
More news about: Intensity Therapeutics Inc.
May 07, 2026, 16:06 ET Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Conn., May 7, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill
More news about: Intensity Therapeutics Inc.
Apr 15, 2026, 09:15 ET Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies
More news about: Intensity Therapeutics Inc.
Mar 27, 2026, 16:12 ET Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
Conn., March 27, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill
More news about: Intensity Therapeutics Inc.
Mar 24, 2026, 08:00 ET Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies
More news about: Intensity Therapeutics Inc.
Mar 12, 2026, 07:30 ET Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
SHELTON, Conn., March 12, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies
More news about: Intensity Therapeutics Inc.
Mar 06, 2026, 07:47 ET Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Conn., March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill
More news about: Intensity Therapeutics Inc.
Feb 13, 2026, 08:58 ET Intensity Therapeutics Announces Reverse Stock Split
Conn., Feb. 13, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill
More news about: Intensity Therapeutics Inc.
Feb 12, 2026, 02:01 ET J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research
SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ -- J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer
More news about: J INTS BIO
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
EGFR-NSCLC companies developing emerging therapies, such as ArriVent BioPharma (NASDAQ: AVBP), Akeso Biopharma (HKG: 9926), Summit Therapeutics (NASDAQ: SMMT), J INTS BIO, Merus (NASDAQ: MRUS), Merck (NYSE: MRK), Kelun-Biotech (HKG: 6990), Genprex (NASDAQ: GNPX), Cullinan Oncology (NASDAQ: CGEM), Taiho Pharma, CSPC
More news about: DelveInsight Business Research, LLP
Jan 13, 2026, 07:47 ET Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
SHELTON, Conn., Jan. 13, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies
More news about: Intensity Therapeutics Inc.
Dec 11, 2025, 07:47 ET Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
SHELTON, Conn., Dec. 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies
More news about: Intensity Therapeutics Inc.
Dec 05, 2025, 07:30 ET Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Conn., Dec. 5, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill
More news about: Intensity Therapeutics Inc.
Dec 04, 2025, 07:47 ET Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
SHELTON, Conn., Dec. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies
More news about: Intensity Therapeutics Inc.
Nov 06, 2025, 16:02 ET Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Conn., Nov. 6, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill
More news about: Intensity Therapeutics Inc.
Oct 31, 2025, 08:00 ET Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
SHELTON, Conn., Oct. 31, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies
More news about: Intensity Therapeutics Inc.
Oct 30, 2025, 07:30 ET Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
SHELTON, Conn., Oct. 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies
More news about: Intensity Therapeutics Inc.
Sep 10, 2025, 07:47 ET Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update
Sept. 10, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill
More news about: Intensity Therapeutics Inc.